

1 **Supporting Information**

2 For
3 **Nontarget Screening of Per- and Polyfluoroalkyl Substances Binding to Human Liver Fatty**
4 **Acid Binding Protein**

5 Diwen Yang^a, Jiajun Han^a, David Ross Hall^a, Jianxian Sun^a, Jesse Fu^a, Steven Kutarna^a, Keith A.
6 Houck^b, Carlie A. LaLone^c, Jon A. Doering^{c,d}, Carla A. Ng^e, Hui Peng^{*a,f}

7 ^a Department of Chemistry, University of Toronto, Toronto, ON, Canada

8 ^b Center for Computational Toxicology and Exposure, Office of Research and Development,
9 United States Environmental Protection Agency, Research Triangle Park, NC, 27711 USA

10 ^c Great Lakes Toxicology and Ecology Division, U.S. Environmental Protection Agency, Duluth,
11 Minnesota 55804 United States

12 ^d National Research Council, U.S. Environmental Protection Agency, Duluth, Minnesota 55804
13 USA

14 ^e Department of Civil & Environmental Engineering, University of Pittsburgh, 3700 O'Hara St,
15 Pittsburgh, USA

16 ^f School of the Environment, University of Toronto, Toronto, ON, Canada

17 ***Corresponding author: Hui Peng**, e-mail: hui.peng@utoronto.ca, Department of Chemistry,
18 University of Toronto, Toronto, Ontario, M5S3H6, Canada.

19 Words 2015

20 Tables 3

21 Figures 8

22 This supporting information provides text and figures addressing (1) Chemical and reagents used;
23 (2) Overexpression of *hL*-FABP; (3) Fluorescence displacement assay; (4) Dissociation constants
24 (K_d) of PFASs binding to *hL*-FABP; (5) Sample collection and preparation; (6) Small molecule
25 analysis with LC-Orbitrap; (7) Proteome analysis with liquid chromatography and high-resolution
26 mass spectrometry; (8) Nontarget/suspect data analysis; (9) The chemical number, name and
27 molecular formula and structures of 74 per- and polyfluoroalkyl substances (PFASs); (10) The
28 inhibition concentration, dissociation constants, peak intensity and retention time of 20 *hL*-FABP
29 ligands; (11) Western blot analysis of overexpressed His-tagged *hL*-FABP. (12) Direct binding of
30 1,8-ANS to *hL*-FABP; (13) Calculation process of dissociation constants (K_d) of PFASs; (14) The
31 dose-response curves of 20 PFASs; (15) Verification of *hL*-FABP in SEC fraction F2 by
32 proteomics; (16) PFOS impurity in NEt-FOSA standards; (17) Confirmation of PFPeS and PFHpS
33 by their authentic standards; (18) Confirmation of the secondary structure of *hL*-FABP via Circular
34 Dichroism (CD) spectrometer.

35 **Chemicals and Reagents.** The characterization of the stability of the 74 standard solutions during
36 storage was in progress by EPA. To confirm the identity of 74 PFASs, 74 PFASs were dissolved
37 in methanol to reach the final concentration of 1 μ M of each PFAS. The PFASs were subjected to
38 LC-Orbitrap for analysis (details are provided below). Stock solutions of 30 mM concentrations
39 of 74 PFASs were prepared in dimethyl sulfoxide (DMSO) and stored at -20 °C. A commercial
40 AFFF technical product was the representative AFFFs used in different Air Force bases in USA.
41 *hL-FABP* pNIC28-Bsa4 plasmid (plasmid #42344) was purchased from Addgene (Cambridge,
42 MA, USA). BL21(DE3) competent *Escherichia coli* was purchased from BioLabs Inc. (Whitby,
43 ON, CA). Isopropyl- β -D-thiogalactopyranoside (IPTG) and 1-anilinonaphthalene-8-sulfonic acid
44 (1,8-ANS) were purchased from Thermo Fisher Scientific (Ottawa, ON, CA). Supelclean™
45 ENVI™-18 solid-phase extraction (SPE) cartridges (6 mL, 1g) were purchased from Sigma-
46 Aldrich (St. Louis, MO, USA). Trypsin Gold (mass spectrometry grade) was obtained from
47 Promega (Madison, WI, USA). Triethyl ammonium bicarbonate buffer (TEAB), tris(2-
48 carboxyethyl)phosphine hydrochloride (TCEP), iodoacetamide, cOmplete Mini EDTA-free
49 protease inhibitor cocktail tablets, and dithiothreitol (DTT) were obtained from Sigma-Aldrich (St.
50 Louis, MO, USA). Phosphate-Buffered Saline tablets, HEPES and tris-HCL were purchased from
51 BioShop Canada Inc. (Burlington, ON, Canada). Ultrapure water, methanol and acetonitrile
52 (HPLC grade) were purchased from Fisher Scientific (Ottawa, ON, CA). Formic acid (mass
53 spectrometry grade) was purchased from EMO Millipore (St. Louis, MO, USA).

54 **Overexpression of *hL-FABP*.** *hL-FABP* pNIC28-Bsa4 plasmid (plasmid #42344) was purchased
55 from Addgene (Cambridge, MA, USA). The plasmid was transformed into BL21 (DE3) strain of
56 *Escherichia coli*. The *hL-FABP* protein was overexpressed by adding in 1 mM IPTG followed by
57 overnight incubation at 18 °C. Bacterial cells were lysed by sonication in a lysis buffer (10 mM

58 HEPES, 100 mM NaCl, 0.2 mM EDTA, 10% glycerol, 0.5 mM DTT and protease inhibitors
59 cocktail (Sigma S8830, pH 7.4)) as described previously.¹ The total protein concentration was
60 measured by the Bradford protein assay. The identity of *hL*-FABP was confirmed by SDS-PAGE
61 and western blot with an anti-His antibody (Figure S1).

62 **Circular Dichroism (CD) Spectroscopy.** Recombinant his-tagged *hL*-FABP were loaded into a
63 circular cuvette with a 1mm pathlength and analyzed on a Jasco J-710 circular dichroism
64 spectrophotometer at room temperature. Spectra was acquired from 800nm to 190 nm with 2 nm
65 resolution, with baseline subtraction of the background PBS buffer. Reference L-FABP CD
66 spectrum downloaded from the *Protein Circular Dichroism Databank*²(reference number
67 CD0004134000). We also used the *PDB2CD* web-application³ to predict *hL*-FABP CD spectrum
68 from structural data produced by Patil et al.⁴ (PDB entry 6DO6) and the SP175 soluble proteins
69 reference database. The CD spectra of purified his-tagged *hL*-FABP is consistent with reference
70 and predicted spectrum (Figure S8), and also the experimental spectra determined in a previous
71 study.⁵ These results demonstrated that the *hL*-FABP protein structure was well preserved
72 during the experiments.

73 **Fluorescence Displacement Assay.** The binding of 74 PFASs to *hL*-FABP was individually
74 determined by the displacement of bound 1,8-ANS from *hL*-FABP as previously described.⁶ To
75 initially determine the interactions between 74 PFASs and *hL*-FABP, we investigated the
76 fluorescence displacement of 1,8-ANS by PFASs at a fixed concentration of 300 μ M. In brief, 1
77 μ L of 4 mM 1,8-ANS was added in 100 μ L buffer A (50 mM tri-HCL, 150 mM NaCl, 1 mM
78 dithiothreitol, pH 8.0) with *hL*-FABP (1 μ M). Following incubation at room temperature for 30
79 min, 1 μ L of the stock solution of each PFASs (final concentration = 300 μ M) was added in
80 fluorescence probe solution ($n = 3$) individually. The mixtures were incubated for 30 min at room

81 temperature. The fluorescence signal was measured via an Infinite 200 PRO multimode plate
82 reader (Tecan Group Ltd., Switzerland) with 350 nm excitation wavelength and emission spectra
83 between 420 nm and 600 nm. The 30 PFASs causing > 10% reduction of fluorescence intensity
84 were considered as potential *hL*-FABP ligands and thus selected for K_d measurement.

85 **Dissociation Constants (K_d) of PFASs Binding to *hL*-FABP.** The dissociation constant (K_{dA}) of
86 1,8-ANS was experimentally derived from the measurement of maximal fluorescence intensities
87 of bound 1,8-ANS at various concentrations (0-50 μ M, $n = 3$) (Figure S2). The one-site binding
88 model based Scatchard equation (eq 1) was fit to the displacement of protein-bound 1,8-ANS to
89 calculate K_{dA} :

$$90 \frac{[L_{ANS}]_f}{r} = \frac{[L_{ANS}]_f}{n} + \frac{K_{dA}}{n} \quad (1)$$

91 where $[L_{ANS}]_f$ represents the concentrations of free 1,8-ANS; K_{dA} represents the dissociation
92 constant of 1,8-ANS; n represents the number of binding sites which is 1 for 1,8-ANS and *hL*-
93 FABP; r is the number of moles of bound 1,8-ANS per mole of *hL*-FABP which is fixed to 1.
94 With the Scatchard equation, the K_{dA} was calculated to be 18.0 μ M, similar to the results
95 reported in a previous study.⁷

96 With K_{dA} values, the dissociation constants (K_d) of PFASs were determined from the
97 displacement of protein-bound 1,8-ANS by PFASs at different concentrations ($n = 3$). Specifically,
98 concentrations of 1.23, 3.7, 11.1, 33.3, 100, 300 μ M were selected for high-affinity PFASs, while
99 only high concentrations (50, 75, 150, 300 μ M) were used for low-affinity PFASs. In brief, 1 μ L
100 of stock solution of each 74 PFASs was individually added into a 100 μ L mixture of *hL*-FABP (1
101 μ M) and 1,8-ANS (40 μ M) in buffer A which had been incubated for 30 min to reach equilibrium
102 before adding PFAS. The measurement of fluorescence intensity was done after 30 min incubation
103 at room temperature. The displacement of 1,8-ANS binding to *hL*-FABP by increasing

104 concentrations of PFAS was corresponding to a reduction in fluorescence intensity. K_d values of
105 PFASs were determined by fitting to a sigmoidal model (Figure S3, SI). The GraphPad Prism V7.0
106 was used to plot dose-response curves in which the IC_{50} value of 9 PFASs or IC_{10} value of 11
107 PFASs were derived.

108 With the $IC_{50/10}$ of each PFASs, the corresponding K_d values were obtained through the
109 Cheng-Prusoff equation⁸:

$$110 \quad f_{PFAS} = \frac{[L_{ANS}]}{K_{dA} \left(1 + \frac{[L_{PFAS}]}{K_d}\right) + [L_{ANS}]} \quad (2)$$

111 where f_{PFAS} represents fractional occupancy of PFAS binding to *h*L-FABP by displacing 1,8-ANS;
112 L_{PFAS} represents the concentration of PFAS; K_d represents dissociation constant of PFAS.

113 Therefore, for high-affinity ligands when IC_{50} could be reliably determined, K_d values were
114 calculated by rearranging eq 2 to eq 3:

$$115 \quad K_d = \frac{IC_{50}}{1 + \frac{[L_{ANS}]}{K_{dA}}} \quad (3)$$

116 Similarly, for low-affinity PFASs for which only IC_{10} is determined, K_d values were
117 calculated by rewriting eq 2 to eq 4:

$$118 \quad K_d = \frac{9 \times IC_{10}}{1 + \frac{[L_{ANS}]}{K_{dA}}} \quad (4)$$

119 **Sample Collection and Preparation.** Water samples were collected from the west end of Lake
120 Niapenco which was reported to be contaminated by AFFF chemicals from John C. Munro
121 International Airport, Hamilton, ON. Water samples were collected using polypropylene tubes
122 which were then stored on ice during the transportation and extracted within 10 hours. Water
123 samples were centrifuged at 4000 g for 10 min at 4 °C. Following centrifugation, 100 mL of water
124 samples were extracted with solid-phase extraction (SPE) cartridges (Supelclean™ ENVITM-18
125 SPE, 6 mL, 1g), a common SPE previously used for nontarget analysis.⁹ The SPE cartridges were

126 preconditioned with 6 mL of methanol and equilibrated with 6 mL of ultra-pure water. Water samples
127 were then passed through the conditioned SPE cartridges at a flow rate of 1–2 drops/s. AFFF chemicals
128 were eluted with 5 mL of methanol. The eluents were reconstituted in 50 μ L of methanol after dryness
129 under nitrogen flow. A procedural blank was incorporated by loading 100 mL of ultrapure water
130 onto the SPE cartridges with the same procedure, and no background contamination was detected.

131 **Small Molecule Analysis with LC-Orbitrap.** PFASs analysis including NTA analysis was
132 conducted using a Q Exactive mass spectrometry equipped with a Vanquish UHPLC system
133 (Thermo Fisher Scientific, USA). Separation of PFASs and AFFF chemicals was achieved with
134 Accucore Vanquish C18 column (50 \times 2.1 mm, 1.5 μ m, Thermo Scientific). The Injection
135 volume was 2 μ L with 1% formic acid in ultrapure water (A) and 1% formic acid in acetonitrile
136 (B) as mobile phases. Initially, 10% B was increased to 80% in 2 min, then increased to 100% at
137 5 min and held static for 3 min, followed by a decrease to initial conditions of 10% B and held for
138 1min to allow for equilibration. The flow rate was 0.15 mL/min. The column and sample
139 compartment temperatures were maintained at 40 $^{\circ}$ C and 4 $^{\circ}$ C, respectively. For the analysis of 74
140 PFASs, data were acquired in full MS mode. Parameters for full scan (100–1000 m/z) switch mode
141 recorded at resolution $R = 70\,000$ (at m/z 200) with a maximum of 3×10^6 ions collected within
142 200 ms. For NTA of AFFF chemicals, data were acquired in data-independent acquisition (DIA)
143 mode. Parameters for full MS scan Parameters for DIA were one full MS¹ scan (100–1000 m/z)
144 recorded at resolution $R = 70\,000$ (at m/z 200) with a maximum of 3×10^6 ions collected within
145 100 ms, followed by DIA MS/MS scan (200–500 m/z) recorded at resolution $R = 35\,000$ (at m/z
146 200) with a maximum of 1×10^5 ions collected within 60 ms. DIA data were collected by use of
147 10 m/z isolation windows per MS/MS scan, in total, there were 30, 10- m/z wide windows between
148 200–500 m/z . Mass spectrometric settings for ESI (-) mode which were the used for both full MS

149 mode and DIA mode were as follows: spray voltage, 2.7 kV; sheath gas flow rate, 30 L/h; auxiliary
150 gas flow rate, 6 L/h; capillary temperature 300 °C.

151 **Proteome Analysis with Liquid Chromatography and High-Resolution Mass Spectrometry.**

152 For proteome analysis, the proteins from each SEC fraction were precipitated with 4-fold volumes
153 of cold acetone at -20 °C followed by re-dissolving in 1M TEAB. The protein samples were then
154 reduced with 5 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP) for 60 min,
155 carboxymethylated with 15 mM iodoacetamide in the dark at room temperature for 30 min. The
156 proteins were then digested with trypsin (4 µg) for 16 hours at 37 °C. Digestion was terminated by
157 adding formic acid to 1% (v/v). The tryptic peptides were analyzed by Q Exactive Quadrupole-
158 Orbitrap Mass Spectrometer (Thermo Fisher Scientific, USA) coupled with a Vanquish UHPLC
159 system (Thermo Fisher Scientific, USA).¹ 3 µL of each sample were loaded on Acclaim PepMap
160 100 C18 LC Columns (75µm × 2cm, nanoViper, 3µm, 100Å, Thermo Fisher Scientific, USA) for
161 analytical separations of peptides. (A) 1% formic acid in acetonitrile (v/v) (B) 1% formic acid in
162 ultrapure water (v/v) were used as mobile phases at a 0.120 mL/min flow rate. Initially, B was
163 increased from 5% to 50% in 6 mins, then increased to 100% in 12 mins, and kept static for 1 min
164 following by a decrease to initial conditions of 5% B and held for 1 min to allow for equilibration,
165 the total method duration was 15 min. The positively charged ions were subjected to 400-1500 *m/z*
166 full scan with 70,000 resolution, 60 ms maximum IT and 3×10^6 AGC target. The secondary mass
167 spectrometry data were acquired under data-dependent single ion monitor mode (dd-SIM) with
168 17,500 resolution, 50 ms maximum IT, 2.0 isolation window, 2×10^5 AGC target, 4×10^4 intensity
169 threshold and 10s dynamic exclusion.

170 **Nontarget/Suspect Data Analysis.** Nontarget data analysis was accomplished with an in-house
171 R program. Raw mass spectrometry files were converted to mzXML format. The peaks were



















172 detected with the XCMS package at a mass tolerance of 2.5 ppm.¹⁰ The peak features were matched
173 across samples with a mass tolerance of 2.5 ppm and retention time window of 20 seconds, after
174 retention time adjustment. The ratio of abundances in F2 from *hL*-FABP lysates to those in F2
175 from wild type *E. coli* lysates, was calculated for each peak feature. The *p*-value of the difference
176 between the two groups was also determined by student's t-test. Only the features exhibiting
177 greater peak intensities (fold change > 10, *p*-value < 0.05) in extracts from *hL*-FABP
178 overexpressing lysates were considered as potential *hL*-FABP ligands. Isotopic peaks and adducts
179 were excluded by matching chromatographic peaks and theoretical mass difference. The final
180 differentiated peak list from the output of the R program was manually checked using MS¹ mass
181 and retention time.

182 The features were searched against PFAS (1,021 PFASs) and AFFF surfactant (869
183 surfactants) libraries established in two recent studies,^{11, 12} with a mass tolerance of 3 ppm.
184 Confidence levels were assigned to all identities according to the Schymanski et al. scale.¹³ In
185 brief, a level 1 confidence was assigned to PFASs for which authentic standards are available for
186 confirmation by matching retention time, MS¹ and MS². In the case of AFFF surfactants, the
187 confidence levels fall to levels 2 or 3, in which molecular ions and fragmentation were matched.
188 For instance, SO₃⁻ and HSO₄⁻ were detected as diagnostic fragments of alkyl ether sulfates.

189 **Table S1:** The summary of 74 per- and polyfluoroalkyl substances (PFASs) from U. S.
 190 Environmental Protection Agency (EPA) PFAS screening library⁴⁸ with chemical number, name,
 191 molecular formula and structure. The PFASs have been categorized based on their chemical
 192 structures. The chemical number is consistent with the U.S.EPA PFAS screening library.

| Category | No | CASRN | Name | Molecular Formula | Structure |
|--------------|----|-------------|--|--|-----------|
| Alcohols | 41 | 2043-47-2 | 4:2 Fluorotelomer alcohol | C ₆ H ₅ F ₉ O | |
| | 70 | 647-42-7 | 6:2 Fluorotelomer alcohol | C ₈ H ₅ F ₁₃ O | |
| | 64 | 678-39-7 | 8:2 Fluorotelomer alcohol | C ₁₀ H ₅ F ₁₇ O | |
| | 11 | 375-01-9 | Heptafluorobutanol | C ₄ H ₃ F ₇ O | |
| | 48 | 355-80-6 | 1H,1H,5H-Perfluoropentanol | C ₅ H ₄ F ₈ O | |
| | 67 | 335-99-9 | Dodecafluoroheptanol | C ₇ H ₄ F ₁₂ O | |
| | 50 | 423-65-4 | 11:1 Fluorotelomer alcohol | C ₁₂ H ₃ F ₂₃ O | |
| | 49 | 679-02-7 | 3-(Perfluoropropyl)propanol | C ₆ H ₇ F ₇ O | |
| | 40 | 3792-02-7 | 4:4 Fluorotelomer alcohol | C ₈ H ₉ F ₉ O | |
| | 61 | 1694-30-0 | 3H-Perfluoro-4-hydroxy-3-penten-2-one | C ₅ H ₂ F ₆ O ₂ | |
| | 32 | 129301-42-4 | 1H,1H,8H,8H-Perfluoro-3,6-dioxaoctane-1,8-diol | C ₆ H ₆ F ₈ O ₄ | |
| | 62 | 374-40-3 | 1-Pentafluoroethylethanol | C ₄ H ₅ F ₅ O | |
| | 30 | 125070-38-4 | 3-(Perfluoro-2-butyl)propane-1,2-diol | C ₇ H ₇ F ₉ O ₂ | |
| | 35 | 376-90-9 | Hexafluoroamylene glycol | C ₅ H ₆ F ₆ O ₂ | |
| | 66 | 77953-71-0 | 3H-Perfluoro-2,2,4,4-tetrahydroxypentane | C ₅ H ₃ F ₇ O ₄ | |
| Carboxylates | 4 | 679-12-9 | 4H-Perfluorobutanoic acid | C ₄ H ₂ F ₆ O ₂ | |
| | 12 | 375-22-4 | Perfluorobutanoic acid | C ₄ HF ₇ O ₂ | |
| | 14 | 914637-49-3 | 2H,2H,3H,3H-Perfluorooctanoic acid | C ₈ H ₃ F ₁₁ O ₂ | |
| | 17 | 375-95-1 | Perfluorononanoic acid | C ₉ HF ₁₇ O ₂ | |

| | | | | | |
|------------|----|-------------|--|-----------------------------|--|
| | 20 | 307-24-4 | Perfluorohexanoic acid | $C_6HF_{11}O_2$ | |
| | 21 | 3825-26-1 | Ammonium perfluorooctanoate | $C_8H_4F_{15}NO_2$ | |
| | 74 | 335-67-1 | Perfluorooctanoic acid | $C_8HF_{15}O_2$ | |
| | 23 | 1763-28-6 | 3,3-Bis(trifluoromethyl)-2-propenoic acid | $C_5H_2F_6O_2$ | |
| | 56 | 243139-64-2 | 3-(Perfluoroisopropyl)-2-propenoic acid | $C_6H_3F_7O_2$ | |
| Sulfonates | 6 | 2795-39-3 | Potassium perfluorooctanesulfonate | $C_8F_{17}KO_3S$ | |
| | 15 | 757124-72-4 | 4:2 Fluorotelomer sulfonic acid | $C_6H_5F_9O_3S$ | |
| | 26 | 3871-99-6 | Potassium perfluorohexanesulfonate | $C_6F_{13}KO_3S$ | |
| | 46 | 1763-23-1 | Perfluorooctanesulfonic acid | $C_8HF_{17}O_3S$ | |
| | 57 | 29420-49-3 | Potassium perfluorobutanesulfonate | $C_4F_9KO_3S$ | |
| | 73 | 375-73-5 | Perfluorobutanesulfonic acid | $C_4HF_9O_3S$ | |
| Amides | 5 | 1652-63-7 | Perfluorooctanesulfonamido ammonium iodide | $C_{14}H_{16}F_{17}N_2O_2S$ | |
| | 9 | 1691-99-2 | N-Ethyl-N-(2-hydroxyethyl)perfluorooctanesulfonamide | $C_{12}H_{10}F_{17}NO_3S$ | |
| | 16 | 31506-32-8 | N-Methylperfluorooctanesulfonamide | $C_9H_4F_{17}NO_2S$ | |
| | 19 | 13485-61-5 | Nonafluoropentanamide | $C_5H_2F_9NO$ | |
| | 24 | 4151-50-2 | N-Ethylperfluorooctanesulfonamide | $C_{10}H_6F_{17}NO_2S$ | |
| | 31 | 662-50-0 | Heptafluorobutyramide | $C_4H_2F_7NO$ | |
| | 38 | 355-81-7 | Perfluoropentanamide | $C_5H_3F_8NO$ | |
| | 58 | 355-66-8 | Octafluoroadipamide | $C_6H_4F_8N_2O_2$ | |
| | 60 | 754-91-6 | Perfluorooctanesulfonamide | $C_8H_2F_{17}NO_2S$ | |





| | | | | | |
|--------|----|-------------|---|---|---|
| | 68 | 355-27-1 | 1H,1H-Perfluoropentylamine | C ₅ H ₄ F ₉ N |  |
| | 71 | 1619-92-7 | 2-Amino-2H-perfluoropropane | C ₃ H ₃ F ₆ N |  |
| | 33 | 31253-34-6 | 2-Aminohexafluoropropan-2-ol | C ₃ H ₃ F ₆ NO |  |
| | 45 | 883498-76-8 | Bis(1H,1H-perfluoropropyl)amine | C ₆ H ₅ F ₁₀ N |  |
| Ethers | 34 | 330562-41-9 | Perfluoro-3,6,9-trioxatridecanoic acid | C ₁₀ HF ₁₉ O ₅ |  |
| | 7 | 55621-21-1 | Perfluoro-3,6-dioxaoctane-1,8-dioic acid | C ₆ H ₂ F ₈ O ₆ |  |
| | 2 | 2144-53-8 | 6:2 Fluorotelomer methacrylate | C ₁₂ H ₉ F ₁₃ O ₂ |  |
| | 10 | 329710-76-1 | 2-(Trifluoromethoxy)ethyl trifluoromethanesulfonate | C ₄ H ₄ F ₆ O ₄ S |  |
| | 13 | 74427-22-8 | 2,2-Difluoroethyl triflate | C ₃ H ₃ F ₅ O ₃ S |  |
| | 27 | 333-36-8 | Flurothyl | C ₄ H ₄ F ₆ O |  |
| | 28 | 863090-89-5 | Perfluoro(4-methoxybutanoic) acid | C ₅ HF ₉ O ₃ |  |
| | 37 | 13252-13-6 | Perfluoro-2-methyl-3-oxahexanoic acid | C ₆ HF ₁₁ O ₃ |  |
| | 1 | 58244-27-2 | Tris(Trifluoroethoxy)methane | C ₇ H ₇ F ₉ O ₃ |  |
| | 18 | 15242-17-8 | Allyl perfluoroisopropyl ether | C ₆ H ₅ F ₇ O |  |
| | 44 | 163702-08-7 | Perfluoroisobutyl methyl ether | C ₅ H ₃ F ₉ O |  |
| | 3 | 28523-86-6 | Sevoflurane | C ₄ H ₃ F ₇ O |  |
| | 52 | 56860-81-2 | Difluoromethyl 1H,1H-perfluoropropyl | C ₄ H ₃ F ₇ O |  |
| | 53 | 1623-05-8 | Heptafluoropropyl trifluorovinyl ether | C ₅ F ₁₀ O |  |
| | 54 | 151772-58-6 | Perfluoro-3,6-dioxaheptanoic acid | C ₅ HF ₉ O ₄ |  |


| | | | | | |
|----------|-----------|-----------------------|--|-------------------|--|
| | 65 | 163702-05-4 | Ethyl perfluorobutyl ether | $C_6H_5F_9O$ | |
| Acetates | 47 | 356-24-1 | Methyl heptafluorobutyrate | $C_5H_3F_7O_2$ | |
| | 36 | 424-18-0 | Methyl perfluorohexanoate | $C_7H_3F_{11}O_2$ | |
| | 39 | 132424-36-3 | Methyl 2H,2H,3H,3H-perfluoroheptanoate | $C_8H_7F_9O_2$ | |
| Others | 22 | 355-95-3 | 1-Propenylperfluoropropane | $C_6H_5F_7$ | |
| | 25 | 239795-57-4 | 2-Vinylperfluorobutane | $C_6H_3F_9$ | |
| | 72 | 2648-47-7 | 5H-Perfluoropentanal | $C_5H_2F_8O$ | |
| | 42 | 375-02-0 | Perfluorobutyraldehyde | C_4HF_7O | |
| | 43 | 356-42-3 | Pentafluoropropanoic anhydride | $C_6F_{10}O_3$ | |
| | 63 | 678-78-4 | Perfluoroglutaryl difluoride | $C_5F_8O_2$ | |
| | 51 | 813-03-6 | 5H-Octafluoropentanoyl fluoride | C_5HF_9O | |
| | 55 | 374-41-4 | Methyl perfluoroethyl ketone | $C_4H_3F_5O$ | |
| | 29 | 406-58-6 | 1,1,1,3,3-Pentafluorobutane | $C_4H_5F_5$ | |
| | 59 | 19430-93-4 | 1H,1H,2H-Perfluoro-1-hexene | $C_6H_3F_9$ | |
| 69 | 1767-94-8 | 6H-Perfluorohex-1-ene | C_6HF_{11} | | |

193 **Table S2:** The inhibition concentration ($IC_{50/10}$), dissociation constants (K_d), LC-MS peak
 194 intensities (concentration at 1 μ M) and retention times of 19 PFASs binding to *h*L-FABP.
 195 Results for the other 55 inactive PFASs are not shown. NMe-FOSA (**16**) is excluded from the
 196 table since its K_d is greater than 1000 μ M even though its peak intensity is very high.


| No | IC_{50} (μ M) | IC_{10} (μ M) | K_d (μ M) | Peak Intensity | Retention time (min) |
|----|----------------------|----------------------|------------------|----------------|----------------------|
| 17 | 13.88 | NA | 4.30 | 2.54E+08 | 4.16 |
| 60 | 18.92 | NA | 5.87 | 3.85E+08 | 4.81 |
| 6 | 26.12 | NA | 8.10 | 5.25E+08 | 4.58 |
| 46 | 26.12 | NA | 8.10 | 5.25E+08 | 4.58 |
| 34 | 26.49 | NA | 8.22 | 2.88E+08 | 4.87 |
| 26 | 36.06 | NA | 11.19 | 3.96E+08 | 3.97 |
| 24 | 53.46 | NA | 16.58 | 2.14E+08 | 5.52 |
| 21 | 60.39 | NA | 18.74 | 3.76E+08 | 3.84 |
| 74 | 60.39 | NA | 18.74 | 3.76E+08 | 3.84 |
| 73 | NA | 41.69 | 116.40 | 3.74E+08 | 3.29 |
| 57 | NA | 44.86 | 125.25 | 3.74E+08 | 3.29 |
| 61 | NA | 48.44 | 135.24 | 1.67E+07 | 2.39 |
| 20 | NA | 50.42 | 140.76 | 7.43E+07 | 3.22 |
| 14 | NA | 56.60 | 158.03 | 9.54E+07 | 4.26 |
| 54 | NA | 90.37 | 252.31 | 3.64E+06 | 3.16 |
| 4 | NA | 125.90 | 351.53 | 2.72E+07 | 1.23 |
| 52 | NA | 256.14 | 715.15 | 7.36E+05 | 3.09 |
| 28 | NA | 291.88 | 814.93 | 4.31E+07 | 2.99 |
| 48 | NA | 328.10 | 916.06 | 6.70E+06 | 3.12 |

199 **Table S3.** Exact masses, retention times, predicted formulas and structures of 11 PFASs in AFFF
 200 technical products binding to *hL*-FABP, identified by the SECC method.


| 201 | <i>m/z</i> | RT (min) | Formula | Structures |
|-----|------------|----------|---|--|
| 202 | 348.9377 | 3.37 | C ₅ F ₁₁ SO ₃ ⁻ |  |
| 203 | | | | |
| 204 | 398.9342 | 3.63 | C ₆ F ₁₃ SO ₃ ⁻ |  |
| 205 | | | | |
| 206 | | | | |
| 207 | 498.9275 | 4.26 | C ₈ F ₁₇ SO ₃ ⁻ |  |
| 208 | | | | |
| | 448.9305 | 3.91 | C ₇ F ₁₅ SO ₃ ⁻ |  |
| | 460.9306 | 3.94 | C ₈ F ₁₅ SO ₃ ⁻ |  |
| | 442.9399 | 3.83 | C ₈ HF ₁₄ SO ₃ ⁻ |  |
| | 480.9367 | 4.05 | C ₈ HF ₁₆ SO ₃ ⁻ |  |
| | 476.9252 | 4.02 | C ₈ F ₁₅ SO ₄ ⁻ |  |
| | 382.9392 | 3.36 | C ₆ F ₁₃ SO ₂ ⁻ |  |
| | 548.9233 | 4.53 | C ₉ F ₁₉ SO ₃ ⁻ |  |
| | 514.8972 | 4.29 | C ₈ ClF ₁₆ SO ₃ ⁻ |  |



209
 210 **Figure S1:** Western blot and SDS-PAGE results of His-tagged *hL-FABP*. (Left) Overexpression
 211 of His-tagged *hL-FABP* in *Escherichia coli* from four biological replicates, detected by western
 212 blot with His-tag antibody. The molecular weight of *hL-FABP* is around 15 kDa. (Right) SDS-
 213 PAGE of purified His-tagged *hL-FABP* where F1 was used for experiments. W1-3 are proteins
 214 in the fractions of washing buffer. F1-5 are His-tagged *hL-FABP* in the fraction of elution buffer.



215
 216 **Figure S2:** Direct binding of 1,8-ANS to *hL-FABP*. (A) fluorescence emission signal with
 217 increasing concentrations of 1,8-ANS in *hL-FABP*. Arrow indicates increasing concentration of
 218 1,8-ANS (0, 1.56, 3.12, 5, 6.25, 10, 12.5, 15, 20, 25, 30, 35, 40, 45, 50 μM). (B) Plot of maximal
 219 emission measured at 480 nm for 1,8-ANS in the presence of 1 μM *hL-FABP* as a function of
 220 1,8-ANS concentration. Values are mean \pm SE, $n = 3$. (C) The scatchler plot of 1,8-ANS
 221 binding to *hL-FABP*.



$$f_{\text{ANS}} = \frac{[L_{\text{ANS}}]}{K_{\text{dA}} + [L_{\text{ANS}}]} \quad (3)$$

$$f_{\text{PFAS}} = \frac{[L_{\text{ANS}}]}{K_{\text{dA}} \left(1 + \frac{[I_{\text{PFAS}}]}{K_{\text{d}}}\right) + [L_{\text{ANS}}]} \quad (4)$$

$$\text{IC}_{50}: f_{\text{PFAS}} = \frac{1}{2} f_{\text{ANS}} \quad (5)$$

$$\frac{[L_{\text{ANS}}]}{K_{\text{dA}} \left(1 + \frac{\text{IC}_{50}}{K_{\text{d}}}\right) + [L_{\text{ANS}}]} = \frac{1}{2} \frac{[L_{\text{ANS}}]}{K_{\text{dA}} + [L_{\text{ANS}}]} \quad (6)$$


$$K_{\text{d}} = \frac{\text{IC}_{50}}{1 + \frac{[L_{\text{ANS}}]}{K_{\text{dA}}}} \quad (7)$$

$$\text{IC}_{10}: f_{\text{PFAS}} = \frac{9}{10} f_{\text{ANS}} \quad (8)$$

$$\frac{[L_{\text{ANS}}]}{K_{\text{dA}} \left(1 + \frac{\text{IC}_{10}}{K_{\text{d}}}\right) + [L_{\text{ANS}}]} = \frac{9}{10} \frac{[L_{\text{ANS}}]}{K_{\text{dA}} + [L_{\text{ANS}}]} \quad (9)$$

$$K_{\text{d}} = \frac{9 \text{IC}_{10}}{1 + \frac{[L_{\text{ANS}}]}{K_{\text{dA}}}} \quad (10)$$

222
 223 **Figure S3:** Calculation process of dissociation constants (K_{d}) of PFASs via dose-response curves
 224 obtained by fluorescence displacement assay. (A) Dose-response curve of PFOS (**46**) with
 225 calculated IC_{50} . (B) Dose-response curve of perfluoro-3,6-dioxaheptanoic acid (**54**) with
 226 calculated IC_{10} . (C) Calculation equations of K_{d} of PFASs.



227
228
229


Figure S4: The dose-response curves of 20 PFASs obtained by fluorescence displacement assay with calculated inhibitory concentration ($\text{IC}_{50/10}$) and dissociation constant (K_d).

(A)


FABP1 plasmid sequence

mhhhhhhssgvdldgtenlyfqsMSFSGKY**QLQSQENFEAFM**
KAIGLPEELIQKGDIKGVSEIVQNGKHF^KFTITAGSK**VIQ**
NEFTVGECELE^TMTGEK^VTVVQLEGNKLV^TTFKNIKSV
TELN^GDIITNTMTLGDIVFKRISKRI


(B)



(C)





(D)



230
231
232
233
234
235
236

Figure S5: Verification of *hL*-FABP in SEC fraction F2 by proteomics. (a) Amino acid sequence of *hL*-FABP Adgene plasmid #42344 with N-terminal hexahistidine tag (lower case); AA in bold are those sequenced in (C) and (D). (B) Proteomic samples were searched against the *hL*-FABP sequence and the *E. coli* K-12 reference proteome (Uniprot #UP000000625). Of the 73 unique peptides detected in all replicates (n = 3), 5 were assigned to *hL*-FABP. (C, D) Representative MS/MS sequence of two unique *hL*-FABP peptides that were detected in all three replicates.


237




238

239

240 **Figure S6:** PFOS impurity in NET-FOSA standard contributes to the activity measured by
 241 fluorescence displacement method. (A) LC-MS results of 0.5 μM of NET-FOSA (orange)
 242 standards with a high concentration of PFOS (blue) detected in standards. (B) Relative
 243 fluorescence intensity of 40 μM 1,8-ANS in 1 μM *hL-FABP* as a function of adding NET-FOSA
 244 (1.23, 3.7 11.11, 33.33, 100, 300 μM). Blue dots indicate the relative fluorescence percentage as
 245 a function of adding NET-FOSA (**24**), orange dots indicate the estimated relative fluorescence
 246 percentage as a function of the impurity PFOS in NET-FOSA (**24**) obtained through calculation.




247



248

249 **Figure S7:** The identities of PFPeS (A), PFHpS (B) in F2 of *hL*-FABP (1, 2 from two replicates)
250 were confirmed by their authentic standards (3).



251
 252 **Figure S8:** (A) Circular Dichroism (CD) spectra of the recombinant poly-his tagged *hL*-FABP
 253 protein in *E. coli* used in this study plotted against reference FABP CD spectra (PCDDDB) and
 254 computational predicted spectra (Predicted); see Experimental Details for additional information.
 255 Differences in peak heights result from differences in sample concentration. (B) High-tension
 256 voltage (HT) of the experimental CD spectrum, the sharp increase around 190 nm accounts for
 257 the corresponding sharp decrease in the experimental CD spectra.

258 **References**

- 259 1. Peng, H.; Saunders, D. M. V.; Sun, J. X.; Jones, P. D.; Wong, C. K. C.; Liu, H. L.; Giesy,
260 J. P. Mutagenic azo dyes, rather than flame retardants, are the predominant brominated
261 compounds in house dust. *Environ. Sci. Technol.* **2016**, *50* (23), 12669-12677.
- 262 2. Whitmore, L.; Miles, A. J.; Mavridis, L.; Janes, R. W.; Wallace, B. A. PCDDDB: new
263 developments at the Protein Circular Dichroism Data Bank. *Nucleic Acids Res.* **2017**, *45* (D1),
264 D303-D307.
- 265 3. Mavridis, L.; Janes, R. W. PDB2CD: a web-based application for the generation of
266 circular dichroism spectra from protein atomic coordinates. *Bioinformatics* **2017**, *33* (1), 56-63.
- 267 4. Patil, R.; Mohanty, B.; Liu, B. A.; Chandrashekar, I. R.; Headey, S. J.; Williams, M.
268 L.; Clements, C. S.; Ilyichova, O.; Doak, B. C.; Genissel, P.; Weaver, R. J.; Vuillard, L.; Halls,
269 M. L.; Porter, C. J. H.; Scanlon, M. J. A ligand-induced structural change in fatty acid-binding
270 protein 1 is associated with potentiation of peroxisome proliferator-activated receptor agonists. *J.*
271 *Biol. Chem.* **2019**, *294* (10), 3720-3734.
- 272 5. Sheng, N.; Li, J.; Liu, H.; Zhang, A. Q.; Dai, J. Y. Interaction of perfluoroalkyl acids with
273 human liver fatty acid-binding protein. *Arch. Toxicol.* **2016**, *90* (1), 217-227.
- 274 6. Velkov, T.; Chuang, S.; Wielens, J.; Sakellaris, H.; Charman, W. N.; Porter, C. J. H.;
275 Scanlon, M. J. The interaction of lipophilic drugs with intestinal fatty acid-binding protein. *J.*
276 *Biol. Chem.* **2005**, *280* (18), 17769-17776.
- 277 7. Sheng, N.; Cui, R. N.; Wang, J. H.; Guo, Y.; Wang, J. S.; Dai, J. Y. Cytotoxicity of novel
278 fluorinated alternatives to long-chain perfluoroalkyl substances to human liver cell line and their
279 binding capacity to human liver fatty acid binding protein. *Arch. Toxicol.* **2018**, *92* (1), 359-369.
- 280 8. Yung-Chi, C.; Prusoff, W. H. Relationship between the inhibition constant (KI) and the
281 concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.
282 *Biochem. Pharmacol.* **1973**, *22* (23), 3099-3108.
- 283 9. Wolf, S. T.; Reagen, W. K. Method for the determination of perfluorinated compounds
284 (PFCs) in water by solid-phase extraction and liquid chromatography/tandem mass spectrometry
285 (LC/MS/MS). *Anal. Methods* **2011**, *3* (7), 1485-1493.
- 286 10. Smith, C. A.; Want, E. J.; O'Maille, G.; Abagyan, R.; Siuzdak, G. XCMS: Processing
287 mass spectrometry data for metabolite profiling using Nonlinear peak alignment, matching, and
288 identification. *Anal. Chem.* **2006**, *78* (3), 779-787.
- 289 11. Garcia, R. A.; Chiaia-Hernandez, A. C.; Lara-Martin, P. A.; Loos, M.; Hollender, J.;
290 Oetjen, K.; Higgins, C. P.; Field, J. A. Suspect Screening of Hydrocarbon Surfactants in AFFFs
291 and AFFF-Contaminated Groundwater by High-Resolution Mass Spectrometry. *Environ. Sci.*
292 *Technol.* **2019**, *53* (14), 8068-8077.
- 293 12. Liu, Y. N.; Dagostino, L. A.; Qu, G. B.; Jiang, G. B.; Martin, J. W. High-resolution mass
294 spectrometry (HRMS) methods for nontarget discovery and characterization of poly- and per-
295 fluoroalkyl substances (PFASs) in environmental and human samples. *Trend. Anal. Chem.* **2019**.
- 296 13. Schymanski, E. L.; Jeon, J.; Gulde, R.; Fenner, K.; Ruff, M.; Singer, H. P.; Hollender, J.
297 Identifying small molecules via high resolution mass spectrometry: communicating confidence.
298 *Environ. Sci. Technol.* **2014**, *48* (4), 2097-2098.